Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anecortave acetate versus sham for prevention of sight-threatening CNV in high-risk dry AMD
2005-001598-93Phase 3Completed
- Sponsor
- Alcon Inc.
- Start
- May 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of anecortave in age-related macular degeneration (AMD) (3 arms), sponsored by Alcon Inc. Primary endpoint: Incidence of sight-threatening CNV. Started May 2005; status: completed.
02
Drugs
anecortave
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on 2005-001598-93.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001598-93.